Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Antiviral Res. 2020 Feb 18;176:104744. doi: 10.1016/j.antiviral.2020.104744

Table 2.

In vitro susceptibility of HBVWT, HBVETVR, and HBVADVR to ETV, ADV and CdFA in HBV-plasmid-transfected HepG2 cells.

IC50 (nM) against
Drug HBVWTCe HBVETVR HBVADVR
ETV 4.1 ± 0.3 >1000 (>250) 1.9± 2.6 (0.5)
ADV 2043.5 ± 858.6 2867.7 ±3897.6 (1.4) 4022.5 ± 923.7 (2.0)
CdFA 153.7 ± 15.1 373.2 ± 63.7 (2.4) 192.6 ± 13.7 (1.3)

The IC50 values were obtained using Southern blotting assay. All IC50 values represent average values (±1 S.D.) from two independent experiments. The numbers in parentheses represent the fold change of the IC50 value of a compound compared to that against HBVWT.